Cantor Fitzgerald analyst Brandon Folkes reiterates an Overweight rating on Insys Therapeutics with a $9 price target following the company's Q4 results. The analyst believes 2019 will be a "pivotal and transformational year" for the company. Insys has two potential filings with its spray platform this year, along with two "significant" data readouts from the company's cannabinoids platform, Folkes tells investors in a post-earnings research note titled "CBD Epilepsy Is a Significant Near-Term Catalyst Not to Be Ignored." Data readouts should drive stock momentum, making 2019 the year in which investors are able to return to Insys Therapeutics and appreciate the value that could be unlocked from within the company's spray and cannabinoids pipeline, adds the analyst.